Fengxi Su

7.9k citations

85 papers · 5.7k indexed · 5 hit papers · h-index 26

Impact in

Cancer Research top 0.2%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Breast Cancer Treatment Studies
Oncology top 2%
- Cancer Cells and Metastasis

Papers in ⓘ

Cancer Research 49
- Breast Cancer Treatment Studies 35
- Cancer-related molecular mechanisms research 10
- MicroRNA in disease regulation 9
Oncology 40
- HER2/EGFR in Cancer Research 10
- Global Cancer Incidence and Screening 10

Co-authors: Erwei Song (33 shared papers)Herui Yao (11 shared papers)Chang Gong (8 shared papers)Qiang Liu (21 shared papers)Fengyan Yu (9 shared papers)Judy Lieberman (2 shared papers)Xiaoqu Hu (2 shared papers)Qiuhui Pan (1 shared paper)
Journals: PLoS ONE (5 papers)Annals of Surgical Oncology (4 papers)Annals of Oncology (3 papers)Cancer Research (3 papers)Medicine (3 papers)
Partner nations: China United States Hong Kong

In The Last Decade

Fengxi Su

82 papers receiving 5.6k citations

Hit Papers

5 papers align trajectories log scale

Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells 2019 · 581 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 Nature Cell Biology
2018 Nature Immunology
2015 Cancer Cell
2011 Molecular Cancer
2007 Cell

Peers

Countries citing papers authored by Fengxi Su

Since Specialization

Citations

This map shows the geographic impact of Fengxi Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengxi Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengxi Su more than expected).

Fields of papers citing papers by Fengxi Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengxi Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengxi Su. The network helps show where Fengxi Su may publish in the future.

Co-authors

The 25 scholars most cited alongside Fengxi Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Fengxi Su Line = papers co-authored together Fengxi Su links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 85 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells Cell ·Fengyan Yu, Herui Yao, Pengcheng Zhu, Xiaoqin Zhang, Qiuhui Pan, Chang Gong, Yijun Huang, Xiaoqu Hu, Fengxi Su, Judy Lieberman, Erwei Song Hit paper breakdown →	2007	1536
2	A Cytoplasmic NF-κB Interacting Long Noncoding RNA Blocks IκB Phosphorylation and Suppresses Breast Cancer Metastasis Cancer Cell ·Bodu Liu, Lijuan Sun, Qiang Liu, Chang Gong, Yandan Yao, Xiaobin Lv, Ling Lin, Herui Yao, Fengxi Su, Dangsheng Li, Mu‐Sheng Zeng, Erwei Song Hit paper breakdown →	2015	746
3	Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells Molecular Cancer ·Mei Yang, Jingqi Chen, Fang Su, Bin Yu, Fengxi Su, Ling Lin, Yujie Liu, Jian‐Dong Huang, Erwei Song Hit paper breakdown →	2011	581
4	Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells Nature Cell Biology ·Fei Chen, Jianing Chen, Linbin Yang, Jiang Liu, Xiaoqian Zhang, Yin Zhang, Qingqiang Tu, Dong Yin, De‐Chen Lin, Ping‐Pui Wong, Di Huang, Yue Xing, Jinghua Zhao, Mengfeng Li, Qiang Liu, Fengxi Su, Shicheng Su, Erwei Song Hit paper breakdown →	2019	581
5	NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death Nature Immunology ·Di Huang, Jianing Chen, Linbin Yang, Qian Ouyang, Jiaqian Li, Liyan Lao, Jinghua Zhao, Jiang Liu, Yiwen Lu, Yue Xing, Fei Chen, Fengxi Su, Herui Yao, Qiang Liu, Shicheng Su, Erwei Song Hit paper breakdown →	2018	345
6	Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2 ⁺ Breast Cancer Growth and Metastasis Science Translational Medicine ·Yandan Yao, Tianmeng Sun, Songyin Huang, Shuang Dou, Ling Lin, Jia-Ning Chen, Jian-bin Ruan, Chengqiong Mao, Fengyan Yu, Mu‐Sheng Zeng, Jianye Zang, Qiang Liu, Fengxi Su, Peter Zhang, Judy Lieberman, Jun Wang, Erwei Song	2012	163
7	Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial Journal for ImmunoTherapy of Cancer ·Jieqiong Liu, Qiang Liu, Ying Li, Qian Li, Fengxi Su, Herui Yao, Shicheng Su, Quanren Wang, Liang Jin, Ying Wang, Wan Yee Lau, Zefei Jiang, Erwei Song	2020	127
8	Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study BMC Cancer ·Yi Chen, Kai Chen, Xiaoyun Xiao, Yan Nie, Shaohua Qu, Chang Gong, Fengxi Su, Erwei Song	2016	125
9	MiR-27 as a Prognostic Marker for Breast Cancer Progression and Patient Survival PLoS ONE ·Wei Tang, Jiujun Zhu, Shicheng Su, Wei Wu, Qiang Liu, Fengxi Su, Fengyan Yu	2012	114
10	Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1 Nature Communications ·Yinghua Zhu, Yujie Liu, Chao Zhang, Junjun Chu, Yanqing Wu, Yudong Li, Jieqiong Liu, Qian Li, Shunying Li, Qianfeng Shi, Liang Jin, Jianli Zhao, Dong Yin, Sol Efroni, Fengxi Su, Herui Yao, Erwei Song, Qiang Liu	2018	110
11	Treatments for Idiopathic Granulomatous Mastitis: Systematic Review and Meta-Analysis Breastfeeding Medicine ·Lei Xin, Kai Chen, Liling Zhu, Erwei Song, Fengxi Su, Shunrong Li	2017	93
12	miR-21 Induces Myofibroblast Differentiation and Promotes the Malignant Progression of Breast Phyllodes Tumors Cancer Research ·Chang Gong, Yan Nie, Shaohua Qu, Jian-You Liao, Xiuying Cui, Herui Yao, Yunjie Zeng, Fengxi Su, Erwei Song, Qiang Liu	2014	75
13	What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis Breast Cancer Research and Treatment ·Jianli Zhao, Jieqiong Liu, Kai Chen, Shunrong Li, Ying Wang, Yaping Yang, Heran Deng, Weijuan Jia, Nanyan Rao, Qiang Liu, Fengxi Su	2014	74
14	Nerve Fibers in Breast Cancer Tissues Indicate Aggressive Tumor Progression Medicine ·Di Huang, Shicheng Su, Xiuying Cui, Ximing Shen, Yunjie Zeng, Wei Wu, Jianing Chen, Fei Chen, Chonghua He, Jiang Liu, Wei Huang, Qiang Liu, Fengxi Su, Erwei Song, Nengtai Ouyang	2014	63
15	Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis Breast Cancer Research and Treatment ·Liling Zhu, Liang Jin, Shunrong Li, Kai Chen, Weijuan Jia, Quanyuan Shan, Stephen D. Walter, Erwei Song, Fengxi Su	2013	50
16	Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer EBioMedicine ·Chang Gong, Weige Tan, Kai Chen, Na You, Shan Zhu, Gehao Liang, Xinhua Xie, Qian Li, Yunjie Zeng, Nengtai Ouyang, Zhihua Li, Mu‐Sheng Zeng, Shi‐Mei Zhuang, Wan-Yee Lau, Qiang Liu, Dong Yin, Xueqin Wang, Fengxi Su, Erwei Song	2016	44
17	A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Research and Treatment ·Meijun Long, Weijuan Jia, Shunrong Li, Liang Jin, Jiannan Wu, Nanyan Rao, Huiyi Feng, Chen Kai, Heran Deng, Fengtao Liu, Fengxi Su, Erwei Song	2011	43
18	Modified effect of urinary cadmium on breast cancer risk by selenium Clinica Chimica Acta ·Xue-Ling Wei, Jianrong He, Yu‐Ling Cen, Yi Su, Lijuan Chen, Ying Lin, Banghua Wu, Fengxi Su, Lu-Ying Tang, Zefang Ren	2014	35
19	A novel six-microRNA-based model to improve prognosis prediction of breast cancer Aging ·Jianguo Lai, Hongli Wang, Zihao Pan, Fengxi Su	2019	35
20	Reduced Let-7a Is Associated with Chemoresistance in Primary Breast Cancer PLoS ONE ·Jiannan Wu, Shunrong Li, Weijuan Jia, Heran Deng, Kai Chen, Liling Zhu, Fengyan Yu, Fengxi Su	2015	34

About Fengxi Su

Fengxi Su is a scholar working on Cancer Research, Oncology, Pathology and Forensic Medicine, Molecular Biology and Surgery, having authored 85 papers that have together received 5.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (35 papers), Breast Lesions and Carcinomas (26 papers), HER2/EGFR in Cancer Research (10 papers), Cancer-related molecular mechanisms research (10 papers), Global Cancer Incidence and Screening (10 papers), MicroRNA in disease regulation (9 papers), Cancer and Skin Lesions (9 papers) and Breast Implant and Reconstruction (8 papers). The work is most often cited by research in Cancer Research (3.6k citations), Oncology (1.5k citations), Molecular Biology (3.7k citations), Immunology (576 citations) and Pathology and Forensic Medicine (436 citations). Fengxi Su has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Erwei Song, Herui Yao, Chang Gong, Qiang Liu, Fengyan Yu, Judy Lieberman, Xiaoqu Hu, Qiuhui Pan, Yijun Huang and Pengcheng Zhu. Their work appears in journals such as PLoS ONE, Annals of Surgical Oncology, Annals of Oncology, Cancer Research and Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact